These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 26200266)

  • 1. FDG-PET/CT as a Predictor of Outcome in EGFR-Mutant Non-Small-Cell Lung Cancer.
    Gold KA; Erasmus JJ
    J Thorac Oncol; 2015 Aug; 10(8):1131-2. PubMed ID: 26200266
    [No Abstract]   [Full Text] [Related]  

  • 2. Monitoring targeted therapy: is fluorodeoxylucose uptake a marker of early response?
    Linden HM; Krohn KA; Livingston RB; Mankoff DA
    Clin Cancer Res; 2006 Oct; 12(19):5608-10. PubMed ID: 17020961
    [No Abstract]   [Full Text] [Related]  

  • 3. Total Lesion Glycolysis in Positron Emission Tomography Can Predict Gefitinib Outcomes in Non-Small-Cell Lung Cancer with Activating EGFR Mutation.
    Keam B; Lee SJ; Kim TM; Paeng JC; Lee SH; Kim DW; Jeon YK; Chung DH; Kang KW; Chung JK; Heo DS
    J Thorac Oncol; 2015 Aug; 10(8):1189-94. PubMed ID: 26200273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib.
    Mileshkin L; Hicks RJ; Hughes BG; Mitchell PL; Charu V; Gitlitz BJ; Macfarlane D; Solomon B; Amler LC; Yu W; Pirzkall A; Fine BM
    Clin Cancer Res; 2011 May; 17(10):3304-15. PubMed ID: 21364032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of ¹⁸F-fluorodeoxyglucose PET-CT in non-small cell lung cancer patients receiving erlotinib (Tarceva); objective and symptomatic responses at 6 and 12 weeks.
    O'Brien ME; Myerson JS; Coward JI; Puglisi M; Trani L; Wotherspoon A; Sharma B; Cook G; Ashley S; Gunapala R; Chua S; Popat S
    Eur J Cancer; 2012 Jan; 48(1):68-74. PubMed ID: 22119198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update: NCCN non-small cell lung cancer clinical practice guidelines.
    Ettinger DS; Kris MG
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 3():S-9-13. PubMed ID: 23570092
    [No Abstract]   [Full Text] [Related]  

  • 7. Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy.
    Fasano M; Della Corte CM; Papaccio F; Ciardiello F; Morgillo F
    J Thorac Oncol; 2015 Aug; 10(8):1133-41. PubMed ID: 26039012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can 3'-deoxy-3'-(18)F-fluorothymidine or 2'-deoxy-2'-(18)F-fluoro-d-glucose PET/CT better assess response after 3-weeks treatment by epidermal growth factor receptor kinase inhibitor, in non-small lung cancer patients? Preliminary results.
    Bhoil A; Singh B; Singh N; Kashyap R; Watts A; Sarika S; Mittal BR
    Hell J Nucl Med; 2014; 17(2):90-6. PubMed ID: 24997081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.
    Zannetti A; Iommelli F; Speranza A; Salvatore M; Del Vecchio S
    J Nucl Med; 2012 Mar; 53(3):443-50. PubMed ID: 22331221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-FDG PET as a surrogate biomarker in non-small cell lung cancer treated with erlotinib: newly identified lesions are more informative than standardized uptake value.
    Bengtsson T; Hicks RJ; Peterson A; Port RE
    J Nucl Med; 2012 Apr; 53(4):530-7. PubMed ID: 22414632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer.
    Eschmann SM; Friedel G; Paulsen F; Reimold M; Hehr T; Budach W; Dittmann H; Langen HJ; Bares R
    Lung Cancer; 2007 Feb; 55(2):165-71. PubMed ID: 17129635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Timing of metabolic response monitoring during erlotinib treatment in non-small cell lung cancer.
    van Gool MH; Aukema TS; Schaake EE; Rijna H; Valdés Olmos RA; van Pel R; Burgers SA; van Tinteren H; Klomp HM;
    J Nucl Med; 2014 Jul; 55(7):1081-6. PubMed ID: 24812245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New CT response criteria in non-small cell lung cancer: proposal and application in EGFR tyrosine kinase inhibitor therapy.
    Lee HY; Lee KS; Ahn MJ; Hwang HS; Lee JW; Park K; Ahn JS; Kim TS; Yi CA; Chung MJ
    Lung Cancer; 2011 Jul; 73(1):63-9. PubMed ID: 21093094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinib.
    Kahraman D; Holstein A; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Dietlein M; Wolf J; Kobe C
    Clin Nucl Med; 2012 Nov; 37(11):1058-64. PubMed ID: 23027207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary TKI resistance in advanced non-small cell lung cancer with EGFR mutation: an open question.
    Giuliani J; Martelli S; Remo A; Bonetti A
    Tumori; 2015 Jul; 101(4):e115-7. PubMed ID: 25953440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
    Kahraman D; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Holstein A; Dietlein M; Wolf J; Kobe C
    J Nucl Med; 2011 Dec; 52(12):1871-7. PubMed ID: 22065872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor tyrosine kinase inhibitors in patients with EGFR wild-type lung cancer: when there is a target, there is a targeted drug.
    Zhou F; Chen X; Zhou C
    J Clin Oncol; 2015 Feb; 33(5):523-4. PubMed ID: 25584007
    [No Abstract]   [Full Text] [Related]  

  • 19. CT findings in non-small-cell lung cancer patients treated with gefitinib or erlotinib.
    Na II; Choe du H; Kim CH; Park SH; Park JH; Lee JC
    J Cancer Res Ther; 2012; 8(2):247-53. PubMed ID: 22842370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer: Proof of Concept for FMISO-PET.
    Arvold ND; Heidari P; Kunawudhi A; Sequist LV; Mahmood U
    Technol Cancer Res Treat; 2016 Apr; 15(2):234-42. PubMed ID: 25759424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.